UBS Group’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$418K Sell
83,724
-15,227
-15% -$76K ﹤0.01% 4975
2025
Q1
$793K Buy
98,951
+432
+0.4% +$3.46K ﹤0.01% 4364
2024
Q4
$732K Buy
98,519
+92,385
+1,506% +$686K ﹤0.01% 4446
2024
Q3
$58.3K Buy
6,134
+2,551
+71% +$24.2K ﹤0.01% 5521
2024
Q2
$44.7K Sell
3,583
-4,130
-54% -$51.5K ﹤0.01% 5629
2024
Q1
$168K Buy
7,713
+7,711
+385,550% +$168K ﹤0.01% 4819
2023
Q4
$18 Buy
+2
New +$18 ﹤0.01% 7862
2023
Q3
Sell
-8
Closed -$680 8025
2023
Q2
$680 Sell
8
-2
-20% -$170 ﹤0.01% 7049
2023
Q1
$4.11K Sell
10
-16
-62% -$6.58K ﹤0.01% 7131
2022
Q4
$31.1K Sell
26
-2
-7% -$2.4K ﹤0.01% 6038
2022
Q3
$22K Buy
28
+25
+833% +$19.6K ﹤0.01% 6148
2022
Q2
$4K Sell
3
-5
-63% -$6.67K ﹤0.01% 7994
2022
Q1
$15K Buy
8
+2
+33% +$3.75K ﹤0.01% 6770
2021
Q4
$30K Buy
+6
New +$30K ﹤0.01% 6280
2021
Q3
Hold
0
8346
2021
Q2
Sell
-5
Closed -$40K 8251
2021
Q1
$40K Buy
5
+2
+67% +$16K ﹤0.01% 5750
2020
Q4
$22K Buy
3
+2
+200% +$14.7K ﹤0.01% 5854
2020
Q3
$8K Sell
1
-4
-80% -$32K ﹤0.01% 6122
2020
Q2
$38K Sell
5
-3
-38% -$22.8K ﹤0.01% 5252
2020
Q1
$57K Sell
8
-3
-27% -$21.4K ﹤0.01% 4839
2019
Q4
$163K Buy
11
+5
+83% +$74.1K ﹤0.01% 4720
2019
Q3
$54K Buy
6
+4
+200% +$36K ﹤0.01% 5219
2019
Q2
$35K Buy
2
+1
+100% +$17.5K ﹤0.01% 5341
2019
Q1
$9K Hold
1
﹤0.01% 6028
2018
Q4
$12K Sell
1
-1
-50% -$12K ﹤0.01% 6204
2018
Q3
$22K Hold
2
﹤0.01% 5832
2018
Q2
$20K Buy
+2
New +$20K ﹤0.01% 5768
2018
Q1
Sell
-1
Closed -$7K 6877
2017
Q4
$7K Buy
+1
New +$7K ﹤0.01% 6237
2017
Q2
Sell
-5
Closed -$9K 6680
2017
Q1
$9K Buy
5
+1
+25% +$1.8K ﹤0.01% 5735
2016
Q4
$10K Buy
4
+3
+300% +$7.5K ﹤0.01% 5950
2016
Q3
$14K Buy
+1
New +$14K ﹤0.01% 5643
2016
Q2
Sell
-1
Closed -$11K 6496
2016
Q1
$11K Buy
+1
New +$11K ﹤0.01% 5746
2015
Q4
Hold
0
6687